A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

NCT00622713 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Rivastigmine transdermal patch

Sponsor

Novartis